RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nov. 9, 2005--Continuing its commitment to providing reliable supplies of the safest possible products, Talecris Biotherapeutics has confirmed its plasma collection and manufacturing processes significantly remove or inactivate enveloped viruses, such as those belonging to the influenza virus family, including the H5N1 virus associated with avian bird flu. With this announcement, patients and physicians can feel confident that transmission of the avian bird flu virus, a current public health concern, is extremely unlikely to occur with the use of Talecris plasma-derived therapeutic proteins.
